

ANNUAL GENERAL MEETING OF SHAREHOLDERS IN NEWBURY PHARMACEUTICALS AB

The annual general meeting of Newbury Pharmaceuticals was held on Wednesday, 10 January 2024. At the meeting 10 771 741 shares were represented, which corresponds to approx. 55 percent of the total number of shares. The summary below shows the resolutions adopted at the AGM. The resolutions were adopted unanimously.

Allocation of the company's result

The AGM resolved to adopt the income statement and balance sheet for the company as well as the consolidated income statement and consolidated balance sheet for the previous financial year. The board of directors and the managing director were discharged from liability for the same period.

The AGM approved the board's proposal that the result should be carried forward.

Fees to the board members and the auditors

The AGM agreed on the following fees to the board and the auditors.

Each one of the board members elected by the AGM (and who are not employed in the group) – 60,000 SEK

Fees to the auditors shall be paid in accordance with approved invoices.

Board members, chairman of the board and auditors

Karl Karlsson, Andreas Hedskog, Anil Okay and Johan Strömqvist were re-elected as board members. Karl Karlsson was re-elected as chairman of the board.

Ernst & Young AB was elected as the company's auditor, with Martin Henriksson as auditor in charge.

Authorization for the board to decide on issue of new shares

The AGM resolved to authorize the board of Newbury Pharmaceuticals AB to decide to issue new shares in the company, in accordance with the board's proposal.

For more information, contact:

Lars Minor, CEO
lars.minor@newburypharma.com
Mobile: +46 72-377 3005

www.newburypharma.com

Press Release
10 January 2024 11:20:00 CET



About Newbury Pharmaceuticals

Newbury Pharmaceuticals is building a pipeline of proprietary and licensed products with focus on specialty and branded products in the Nordics. Newbury aims to make a difference by offering treatment solutions within areas like oncology, rare diseases and neurology. The portfolio is built by leveraging experience and extensive international network. Newbury offers strategic partnerships of innovation for the benefit of the Nordic healthcare market.

Västra Hamnen Corporate Finance is the Company's Certified Adviser on Nasdaq First North and can be reached at ca@vhcorp.se or +46 (0) 40 200 250.

Attachments

[ANNUAL GENERAL MEETING OF SHAREHOLDERS IN NEWBURY PHARMACEUTICALS AB](#)